3rd Quarter - Report
W STRATEGIES, LLC for RAPTOR PHARMACEUTICAL CORP.
Firm
Client
Income
$30,000
Expenses
—
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Issues related to orphan drugs and the value of innovative medicines. March 2016 CMS proposed rule implementing a new Part B drug payment model. H.R. 5122 - To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARREN WILLCOX | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.